On January 14 of 2016, ImmuneOnco announced acceptance of the patent application on a novel engineered recombinant chimeric PD-1 receptor (CPR).
ImmuneOnco Biopharma Co., Ltd, an early-stage immunotherapy company dedicated to development and commercialization of novel cancer immunotherapy products,
ImmuneOnco Biopharma Co., Ltd today announced closing of first round fund-raising in pre-A round as of the amount of 25 million RMB
On November 16 of 2015, we have successfully confirmed acceptance of the application of PCT (PCT/CN2015/094739) on a novel engineered recombinant protein with two specific biological...
On November 12 of 2015, we have successfully filed the application of trademark registration on “X-TANK”, in which “X” represents any disease target, “TANK” stands for “Target-Activa...
ImmuneOnco Biopharma Co., Ltd was incorporated in June of 2015 in Free Trade Zone of Shanghai, China.
Bio pharmaceutical industry index last week (2015/11/09-2015/11/13) rose 1.33%, leading the Shanghai and Shenzhen 300 index 2.57 percentage points; in the 28 on...
TEL:+86-21-58356573
EMAIL:wenzhi.tian@immuneonco.com
ADDRESS:Room 502, Harley Road No.1043, Pudong New district, Shanghai
CopyRight © 2014-2015 No.15048165